Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, on Tuesday reported financial results for the third quarter of 2023. Revenues
Categories
Biotechnology
Gilead Sciences Q3 2023 Earnings: Stay tuned for the live earnings call and real-time transcript
Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, will be reporting third-quarter results today at 4:00 p.m. ET. Listen to
VRTX Earnings: Highlights of Vertex Pharmaceuticals’ Q3 2023 results
Healthcare company Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) on Monday reported an increase in revenues for the third quarter of 2023. The company also
Vertex Pharma Q3 2023 Earnings Call: Listen Live and Follow Along with the Real-Time Transcript
Healthcare firm Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is scheduled to publish earnings for the third quarter of 2023, today at 4:00 p.m.
REGN Earnings: Regeneron Pharma Q3 revenue, adj. profit increase
Healthcare firm Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported an increase in adjusted earnings and revenues for the third quarter of
AMGN Earnings: Highlights of Amgen’s Q3 2023 financial results
Biotechnology firm Amgen Inc. (NASDAQ: AMGN) on Tuesday reported higher revenues and adjusted earnings for the third quarter of 2023. The company
BMY Earnings: Highlights of Bristol-Myers Squibb’s Q3 2023 results
Biotechnology company Bristol Myers Squibb (NYSE: BMY) Friday reported mixed results for the third quarter of 2023. The company also provided guidance
Earnings Summary: Highlights of Centene Corp’s Q3 2023 earnings report
Healthcare service provider Centene Corporation (NYSE: CNC) on Tuesday announced third-quarter 2023 earnings results, reporting a sharp increase in revenues and adjusted
Ocean Biomedical forms JV with Virion Therapeutics to find treatments for cancer and chronic infectious diseases
Biotechnology company Ocean Biomedical, Inc. (NASDAQ: OCEA) entered into a joint venture with Virion Therapeutics, LLC, to expedite and expand the latter’s
Ocean Biomedical’s cancer-targeting antibody candidate shows effective tumor reduction against a subset of NSCLC with EGFR mutations
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biotechnology company that operates by partnering with leading researchers to accelerate new discoveries in the healthcare
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biotechnology company that operates by partnering with leading researchers to accelerate new discoveries in the
Illumina, Inc Q2 2023 Earnings Conference Call Insights
Key highlights from Illumina, Inc (ILMN) Q2 2023 Earnings Concall Management Update: [00:07:42] ILMN now expects to ship more than 390 NovaSeq
Ocean Biomedical provides update on programs in malaria, fibrosis, and multiple cancers
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday provided an update on its broad range of programs in malaria, fibrosis, and multiple cancers.
Earnings Summary: Highlights of Illumina’s Q2 2023 results
Biotechnology company Illumina, Inc. (NASDAQ: ILMN) on Wednesday announced financial results for the second quarter of 2023. Second-quarter revenue came in at
Earnings Summary: Highlights of Organon’s Q2 2023 results
Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and earnings for the second quarter of 2023. Second-quarter revenue came
Charles River Laboratories International, Inc Q2 2023 Earnings Conference Call Insights
Key highlights from Charles River Laboratories International, Inc (CRL) Q2 2023 Earnings Concall Q&A Highlights: [00:34:34] Sandy Draper with Guggenheim asked if
Earnings Summary: Charles River Laboratories reports Q2 2023 results
Pharma company Charles River Laboratories International, Inc. (NYSE: CRL) on Wednesday reported financial results for the second quarter of 2023. For the
Ocean Biomedical’s share price target averages $18.21 amid continued progress in research programs
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Wednesday shared collective analyst research coverage from three firms, with current Buy recommendations and share price
Earnings Summary: Bio-Techne Corp (TECH) reports higher Q4 profit, revenue
Biotechnology company Bio-Techne Corporation (NASDAQ: TECH) on Tuesday announced financial results for the fourth quarter of 2023, reporting an increase in profit.
Earnings Summary: Zoetis (ZTS) reports fiscal 2023 Q2 results
Animal healthcare company Zoetis Inc. (NYSE: ZTS) announced operating results for the second quarter, reporting higher adjusted profit and sales. Zoetis' June-quarter
AMGN Earnings: Everything you need to know about Amgen’s Q2 results
Amgen Inc. (NASDAQ: AMGN) on Friday reported higher revenues and adjusted earnings for the second quarter of 2023. The biotechnology firm also